13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

What to ensure before the creation of a viable spinout opportunity?

What to ensure before the creation of a viable spinout opportunity?

What does viable mean for TTOs, and do we have the same definition everywhere? On which grounds are TTOs advising to create a spin-off rather than out-licensing the IP or a contract-based R&D collaboration? Which are the benefits, limits, constraints and indication of the spin-out model? What are the key factors to create a well-conceived spin-off company, how to exploit and maximise the value creation?

Jürgen Walkenhorst

Managing Director
Germany
Life Science Nord

Rafaela Kunz

Open Innovation Consultant, Biotechnologist & IP Expert
Germany
InseaConsulting

Pierre D’Epenoux

CEO
France
Imcheck Therapeutics

Anna Bialek Jaworska

Professor & Economist
Poland
University of Warsaw
Scroll to Top
  • No products in the cart.